Stock Ratings / Health Care / HCM / financials

RCUS (35) PGEN (35) PHVS (63) SUPN (56) ⌘ Pro Terminal →

HUTCHMED (China) Limited (HCM) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$13.59 +2.03% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $13.61

HUTCHMED (China) Limited (HCM) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $2.37B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $13.61 (+0.18%)🧬 Dilution Drag (+1.36% YoY Shares)⚙️ Cash Engine: 4/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (46/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.1% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk C-

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for HCM)Realized 20D OHLCV Swing Band: ±5.6%

Deterministic 5-Pillar Attribution (46/100 Composite)

🔍 WHY HCM SCORES 46/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+12/20 pts (26% of score)

Altman Z-Score 3.63 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (26% of score)

FRED Regime × Technicals: 58% of 52W Range • RSI-14 at 41.1 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Cash Engine Quality4/20 pts (-16 pt drag)

Capital intensity & 0% operating margin leave 16 pts on the table

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$14.10-0.4% Next Q

Q2 (-2Q)

Grade C-$14.05+2.2% Next Q

Q3 (-1Q)

Grade D$14.36-5.4% Next Q

Current

Grade D$13.59-6.1% Hist 90D α

Trajectory: C- (54) → D (46)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a HCM Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While HCM currently carries a cautious 46/100 (D) rating due to Cash Engine Quality (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($13.65) and Max Pain ($14.27) forces dealer call-delta covering toward $17.15.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.36% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $HCM• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “HCM Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 46%NO 54%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How HCM Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $838.0M

FY24

Rev $630.2M

FY25

Rev $548.5M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$548.5M	38.7%	-7.1%	$456.9M	-$78.8M	-2.5%
FY 2024	$630.2M	44.6%	-6.9%	$37.7M	-$17.4M	-5.2%
FY 2023	$838.0M	38.7%	2.2%	$100.8M	$219.3M	-2.5%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring HCM)

✓Walkthrough of HCM's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

HCM // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.12%🛡️ HOLDING TREND SUPPORT

2026-10-30O $13.35H $13.59L $13.14C $13.59VOL 33.5K

RES: $16.54SUP: $13.20SMA50: $13.65SMA200: $13.22

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

HCM Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 HCM Butterfly Map → + Track HCM →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

-13.3%/yr Implied 5Y Growth

vs. -13.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on HCM today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for HCM. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for HCM today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (HCM)

Health Care Rank #439 of 1016 ⚔️ RCUS vs HCM Full Matrix →

1. Head-to-Head Health Care Peer Comparison (HCM vs. RCUS, PGEN, PHVS, SUPN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, HUTCHMED (China) Limited (HCM) ranks #439 by composite RQD confidence (46/100, grade D) and #227 by equity capitalization ($2.37B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while HCM leads on capital efficiency and profitability with -2.5% ROIC and — gross margin. PHVS currently holds the highest overall quantitative score in the immediate peer group at 63/100 (C) compared with HCM at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
HCM ACTIVE HUTCHMED (China) Limited	D	46/100	5.2x	—	-2.5%	+2.03%	$2.37B	Benchmark Subject
RCUS Arcus Biosciences Inc.	D-	35/100	—	—	-35.0%	+1.20%	$2.37B	/rcus-vs-hcm →
PGEN Precigen Inc.	D-	35/100	—	—	-35.0%	+9.21%	$2.38B	/pgen-vs-hcm →
PHVS Pharvaris N.V.	C	63/100	—	—	—	+2.32%	$2.34B	/phvs-vs-hcm →
SUPN Supernus Pharmaceuticals Inc.	D+	56/100	—	89.6%	-4.5%	+1.85%	$2.43B	/supn-vs-hcm →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001648257

In its most recent audited fiscal period (FY2025, filed 2025-12-31), HUTCHMED (China) Limited (HCM) reported GAAP revenue of $548.5M (-13.0% vs. FY2024 revenue of $630.2M , and -34.5% cumulative change since FY2023) , GAAP net income of $456.9M, operating cash flow of -$64.7M, and free cash flow of -$78.8M (-352.0% YoY). On the balance sheet, HCM closed FY2025 with $1.75B in total assets against $68.2M in total debt (Altman Z-Score: 3.63, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$548.5M	$456.9M	-$64.7M	-$78.8M	$1.75B	$68.2M
FY2024 (FY)	2024-12-31	$630.2M	$37.7M	$497.0K	-$17.4M	$1.27B	$59.4M
FY2023 (FY)	2023-12-31	$838.0M	$100.8M	$219.3M	$219.3M	—	—

3. HCM Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is HCM stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, HUTCHMED (China) Limited (NASDAQ: HCM) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $13.59 (+2.03% 1D, market cap $2.37B). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 11/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, HCM ranks #439 in composite RQD confidence.

How does HCM compare to RCUS and PGEN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), HCM carries a Roarable D (46/100 RQD), trailing P/E of 5.2x, gross margin of —, and ROIC of -2.5%. By comparison, RCUS (Arcus Biosciences Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.37B) and PGEN (Precigen Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.38B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while HCM leads on capital efficiency (-2.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for HCM?

Per HCM's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001648257), HUTCHMED (China) Limited generated $548.5M in revenue (-13.0% YoY), $456.9M in net income, and -$78.8M in free cash flow against $1.75B in total assets and $68.2M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is HCM trading relative to its 50-day, 200-day, and 52-week technical levels?

HCM last traded at $13.59 (+2.03% on volume of 34,280 shares), positioning the stock -0.44% below its 50-day simple moving average ($13.65) and +2.80% above its 200-day simple moving average ($13.22). Across its 52-week range of $9.77 to $16.33, HCM sits at the 58.2% percentile with a 14-day RSI of 41.1 (NEUTRAL RANGE) and an implied next-earnings move of ±5.6% ($12.83 to $14.35).

HCM Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is HUTCHMED (China) Limited (HCM)?

In FY 2025 (10-K), HCM converted $548.5M of revenue into a 38.7% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: HCM RQD Cockpit HCM 12M Forecast HCM Earnings & Move HCM Dividends & DRIP HCM Insiders & 13F HCM Whale Options HCM Profit Sankey HCM News & Why